Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Moderna stock in Canada | $206.07

Own Moderna shares in just a few minutes.

Moderna is a biotechnology business based in the US. Moderna stocks (MRNA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $206.07 – an increase of 11.38% over the previous week. Moderna employs 1,300 staff and has a trailing 12-month revenue of around $2.7 billion.

How to buy Moderna stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: MRNA in this case.
  5. Research Moderna stocks. The platform should provide the latest information available.
  6. Buy your Moderna stocks. It's that simple.

How has Coronavirus impacted Moderna's stock price?

Since the stock market crash in March caused by coronavirus, Moderna's stock price has had significant positive movement.

Its last market close was $206.07, which is 91.15% up on its pre-crash value of $18.23 and 1,050.59% up on the lowest point reached during the March crash when the stocks fell as low as $17.91.

If you had bought $1,000 worth of Moderna stocks at the start of February 2020, those stocks would have been worth $1,303.79 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $10,111.85.

Moderna stock price

Use our graph to track the performance of MRNA stocks over time.

Moderna stocks at a glance

Information last updated 2021-06-10.
Latest market close$206.07
52-week range$54.21 - $227.71
50-day moving average $175.414
200-day moving average $151.0552
Wall St. target price$181.17
PE ratio 142.366
Dividend yield N/A (0%)
Earnings per share (TTM) $1.492

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Deposit and trade $100 and get a $50 bonus.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Moderna stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Moderna price performance over time

Historical closes compared with the last close of $206.07

1 week (2021-06-02) 7.55%
1 month (2021-05-13) 37.50%
3 months (2021-03-12) 50.43%
6 months (2020-12-11) 31.31%
1 year (2020-06-12) 232.37%
2 years (2019-06-13) 1,175.19%

Is Moderna under- or over-valued?

Valuing Moderna stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Moderna's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Moderna's P/E ratio

Moderna's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 142x. In other words, Moderna stocks trade at around 142x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stocks or simply that they're over-valued.

Moderna's EBITDA

Moderna's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$673.1 million.

The EBITDA is a measure of a Moderna's overall financial performance and is widely used to measure a its profitability.

Moderna financials

Revenue TTM USD$2.7 billion
Operating margin TTM 23.2%
Gross profit TTM USD$-574,877,000
Return on assets TTM 5.37%
Return on equity TTM 21.83%
Profit margin 21.88%
Book value $9.571
Market capitalisation USD$85.3 billion

TTM: trailing 12 months

How to short and sell Moderna stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "MRNA.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 11.8 million Moderna stocks held short by investors – that's known as Moderna's "short interest". This figure is 0.9% down from 11.9 million last month.

There are a few different ways that this level of interest in shorting Moderna stocks can be evaluated.

Moderna's "short interest ratio" (SIR)

Moderna's "short interest ratio" (SIR) is the quantity of Moderna stocks currently shorted divided by the average quantity of Moderna stocks traded daily (recently around 9.3 million). Moderna's SIR currently stands at 1.27. In other words for every 100,000 Moderna stocks traded daily on the market, roughly 1270 stocks are currently held short.

However Moderna's short interest can also be evaluated against the total number of Moderna stocks, or, against the total number of tradable Moderna stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.03% of the outstanding stocks (for every 100,000 Moderna stocks in existence, roughly 30 stocks are currently held short) or 0.0403% of the tradable stocks (for every 100,000 tradable Moderna stocks, roughly 40 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Moderna.

Find out more about how you can short Moderna stock.

Moderna stock dividends

We're not expecting Moderna to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Moderna stock price volatility

Over the last 12 months, Moderna's stocks have ranged in value from as little as $54.21 up to $227.71. A popular way to gauge a stock's volatility is its "beta".

MRNA.US volatility(beta: 1.47)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.4708. This would suggest that Moderna's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Moderna overview

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site